CRL Trading Analysis - 10/22/2026 11:29 AM — TRU-SENTIMENT

News Headlines & Context

Charles River Laboratories (CRL) has seen elevated attention in the contract research organization (CRO) space. Based on general knowledge, recent relevant context includes:

• Large biopharma clients have resumed outsourced preclinical trial volumes, supporting CRO demand recovery into Q4 2026.
• CRL announced expanded capacity at its European safety assessment facilities, a potential multi-year revenue catalyst.
• Industry headlines noted pricing pressure in early-stage discovery services, a margin concern for smaller sponsors.
• No confirmed near-term earnings date in provided data, but fiscal year end per fundamentals is 2025-12-01, with next major options expiration 2026-11-20.
• Broader rate-cut expectations have lifted richly-valued healthcare equities, aligning with CRL's sharp October rally.

Context: The bullish options flow and strong daily price extension coincide with a sector tailwind, though fundamentals show negative EPS, suggesting the move is sentiment- and momentum-driven rather than earnings-backed.

Fundamental Analysis

Based strictly on the embedded FUNDAMENTALS data for CRL:

• Trailing EPS is -4.85; company is currently unprofitable on a trailing basis.
• Trailing P/E is 684.90, reflecting negative earnings quality and extreme valuation multiple.
• PEG ratio, forward P/E, forward EPS, profit margins, ROE, debt-to-equity, and free cash flow are all null/unavailable in data.
• Market cap is $16,642,531,485.00 with 47,739,000.00 shares outstanding.
• Dividend yield is 0.00%; no dividend declared (ex-dividend date null).
• Beta is 1.48 (above market volatility); historical volatility is 44.93%.
• 52-week range: low $146.20, high $348.95 (current price near top of range).
• Institutional ownership is 90.41%, indicating heavy institutional dominance.
• Average volume 1,037,000.00 vs 20-day volume avg 686,991.00 (recent volume above average).
• Analyst target mean price and recommendation key are null — no street consensus in data.

Fundamentals diverge sharply from the technical picture: price is at 52-week highs with bullish flow, yet trailing EPS is negative and valuation is extreme. This suggests the rally is technically/sentiment driven, not fundamentally confirmed.

Current Market Position

Current price per indicators is $346.98 (2026-10-21 close). Minute bars show 2026-10-22 11:00 last close $348.75, with intraday high $349.60.

Recent daily action: 2026-10-20 close $316.80 → 2026-10-21 close $346.98 (gain of $30.18, ~9.53% on volume 2,100,767 vs 20d avg 686,991). 30-day high $348.63, low $267.27.

Intraday minute bars (2026-10-21 09:30 to 2026-10-22 11:00) show steady climb from $313.83 to $348.75 with higher highs and higher lows — strong intraday momentum.

Technical Analysis

SMAs are aligned bullishly: price $346.98 > SMA 5 $314.04 > SMA 20 $302.03 > SMA 50 $291.69 (no bearish crossover). RSI 76.51 indicates overbought momentum. MACD histogram +1.93 (bullish). Price is above Bollinger upper $326.57 (expansion, not squeeze). 30-day range: price at $346.98 is 96.4% of range from low $267.27 to high $348.63 — near top.

True Sentiment Analysis (Delta 40-60 Options)

Per embedded True Sentiment data (2026-10-22):

Call Dollar Volume: $22,870.00 (76.3%) Put Dollar Volume: $7,090.00 (23.7%) Total: $29,960.00

Sentiment is Bullish. 7 call contracts vs 2 put contracts; 4 call trades vs 2 put trades. Pure directional conviction favors calls. Filter ratio 1.6% (6 of 382 options analyzed).

Notable divergence: Option spread recommendation engine returned "no_recommendation" citing divergence between bullish sentiment and technicals showing "no clear direction" — though embedded technicals show clear bullish alignment, the engine's view differs. This is a sentiment/technical caution flag.

Key Price Levels (Observational Only)